Targeting NaV1.7 with selective inhibitor for cancer treatment may offer greater benefit, as this strategy not only inhibits cancer metastasis but also relieves cancer pain associated with treatments such as chemotherapy-induced neuropathic pain (CINP) (Quintão et al., 2019) and/or pain from the disease itself (Eijkelkamp et al., 2012). Here, SCN9A is linked to cancer.